Bradley J. Bolzon PhD - 24 Feb 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GLUE
Reported as of: 24 Feb 2021
Net transaction value: +$15,149,998
SEC form: 4
Accepted by SEC: 25 Jun 2021, 17:00:33 UTC
Next SEC filing: 14 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

Bradley J. Bolzon PhD filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 25 Jun 2021.

Key facts

This page summarizes Bradley J. Bolzon PhD's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 25 Jun 2021, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$15,149,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLUE transaction Derivative

Series B convertible preferred stock

Award

Transaction value: $3,000,000
Shares: +1,500,000
Change %: +100%
Price: $2.00
Shares after: 3,000,000
Date: 24 Feb 2021
Ownership: By Versant Capital VI, L.P.
Underlying class: Common Stock
Underlying amount: 424,869
Exercise price
Footnotes: F1, F2, F3

GLUE transaction Derivative

Series B convertible preferred stock

Award

Transaction value: $4,150,000
Shares: +2,075,000
Change %: +100%
Price: $2.00
Shares after: 4,150,000
Date: 24 Feb 2021
Ownership: By Versant Vantage I, L.P.
Underlying class: Common Stock
Underlying amount: 587,735
Exercise price
Footnotes: F1, F2, F4

GLUE transaction Derivative

Series C convertible preferred stock

Award

Transaction value: $7,999,998
Shares: +2,699,328
Change %
Price: $2.96
Shares after: 2,699,328
Date: 11 Mar 2021
Ownership: By Versant Vantage I, L.P.
Underlying class: Common Stock
Underlying amount: 764,573
Exercise price
Footnotes: F1, F2, F4

GLUE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +47,132
Change %
Price: $0.000000
Shares after: 47,132
Date: 23 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,132
Exercise price: $19.00
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.

Footnote F2

This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.

Footnote F3

Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

Footnote F4

Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

Footnote F5

This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021.